The San Diego-based company manufacturers continuous glucose monitoring systems for diabetic patients.
Until now, the company’s G-Series model has been considered the gold standard, while its competitor Abbott Laboratories (NYSE: ABT) offered a cheaper, user-friendly alternative with the FreeStyle Libre, according to Spruce Point.
Abbott is set to release the Libre 2 in the U.S. and Spruce Point said the launch will close most if not all technological gaps with Dexcom’s G-Series.
This move will put heavy pressure on Dexcom profits with little downside to Abbott's margin, the report said.
“The Street believes that the downmarket Libre is not a serious threat to Dexcom’s market, but the LIbre has taken [greater than 70 percent] incremental share of the U.S. Type 1 market and [greater than 95 percent] incremental share of the U.S. Type 2 market since first being released in the U.S."
Dexcom has few avenues for near-term patient growth and will be effectively locked out of the Type 2 market until it releases a cheaper, downmarket CGM similar to the Libre, according to Spruce Point.
“We see 45-60-percent near-term downside in DXCM shares after disappointing sales growth and a multiple re-rating, and even more potential future downside on long-term price pressure."
DexCom shares were down 3.13 percent at $141.59 at the time of publication Thursday.
The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs
Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
Photo courtesy of Dexcom.
Latest Ratings for DXCM
|Feb 2019||Morgan Stanley||Maintains||Equal-Weight||Equal-Weight|
|Jan 2019||Morgan Stanley||Maintains||Equal-Weight||Equal-Weight|
View More Analyst Ratings for DXCM
View the Latest Analyst Ratings
See more from Benzinga
- 6 Stocks Moving In Wednesday's After-Hours Session
- BofA Downgrades Michaels, Morgan Stanley Stays Bullish After Q4 Print
- Micron Reports Q2 Earnings Beat
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.